NR (Nicotinamide riboside)
Aliases: Niagen · Tru Niagen
Last verified: 2026-09-23
The short version
A vitamin B3 form — the NAD+ precursor with the best regulatory status (FDA GRAS/NDI, EU novel food). Reliably raises NAD+ in humans.
Identity & type
- Molecular type
- mali molekul
- Origin
- A vitamin B3 form — the NAD+ precursor with the best regulatory status (FDA GRAS/NDI, EU novel food).
Mechanism of action
NR → NMN → NAD+ (NRK pathway).
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 300–1000 mg/day.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
300–1000 mg/day. Similar to NMN with better regulatory status: subtle energy and recovery; the community often considers it "calmer" than NMN.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Similar to NMN with better regulatory status: subtle energy and recovery; the community often considers it "calmer" than NMN.
Protocol — official vs community
Official / label
Supplement. Trials used 250–2,000 mg oral daily; NR elevates NAD+ with published human pharmacokinetics.
- 01Flat daily dosing
Duration: Trial-defined.
Better human PK data than NMN; same unresolved clinical-outcome question.
Community (anecdotal)
300–500 mg oral daily, morning.
- Cycle:
- Continuous.
- Break:
- None.
NR vs NMN is mostly a bioavailability argument; neither has proven outcomes.
Human evidence
Multiple RCTs: +40–90% NAD+; clinical outcomes (metabolic, neuro) mostly neutral or modest.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Excellent tolerability; rare GI upset.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use